PRQR
Price:
$1.855
Market Cap:
$136.64M
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and researc...[Read more]
Industry
Biotechnology
IPO Date
2014-09-18
Stock Exchange
NASDAQ
Ticker
PRQR
According to ProQR Therapeutics N.V.’s latest financial reports and current stock price. The company's current PE Ratio is -6.18. This represents a change of -11.50% compared to the average of -6.98 of the last 4 quarters.
The mean historical PE Ratio of ProQR Therapeutics N.V. over the last ten years is -6.89. The current -6.18 PE Ratio has changed 8.87% with respect to the historical average. Over the past ten years (40 quarters), PRQR's PE Ratio was at its highest in in the March 2015 quarter at 505.65. The PE Ratio was at its lowest in in the December 2014 quarter at -51.29.
Average
-6.89
Median
-5.83
Minimum
-16.36
Maximum
-1.60
Discovering the peaks and valleys of ProQR Therapeutics N.V. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 694.53%
Maximum Annual PE Ratio = -1.60
Minimum Annual Increase = -77.62%
Minimum Annual PE Ratio = -16.36
Year | PE Ratio | Change |
---|---|---|
2023 | -5.27 | 38.11% |
2022 | -3.81 | -47.95% |
2021 | -7.33 | 98.61% |
2020 | -3.69 | -42.25% |
2019 | -6.39 | -49.68% |
2018 | -12.70 | 694.53% |
2017 | -1.60 | -42.46% |
2016 | -2.78 | -68.98% |
2015 | -8.96 | -45.27% |
2014 | -16.36 | -77.62% |
The current PE Ratio of ProQR Therapeutics N.V. (PRQR) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.47
5-year avg
-5.30
10-year avg
-6.89
ProQR Therapeutics N.V.’s PE Ratio is greater than Annexon, Inc. (-6.50), less than Arrowhead Pharmaceuticals, Inc. (-5.12), greater than Day One Biopharmaceuticals, Inc. (-7.39), less than Terns Pharmaceuticals, Inc. (-6.06), greater than Alnylam Pharmaceuticals, Inc. (-428.77), greater than Wave Life Sciences Ltd. (-9.04), greater than Blueprint Medicines Corporation (-26.44), greater than Apellis Pharmaceuticals, Inc. (-15.28), less than Assembly Biosciences, Inc. (-2.10), less than Spero Therapeutics, Inc. (4.06), less than Achilles Therapeutics plc (-0.45), less than Instil Bio, Inc. (-0.78), less than Neoleukin Therapeutics, Inc. (-0.98), less than CytomX Therapeutics, Inc. (9.19), less than NextCure, Inc. (-0.65), less than Nuvation Bio Inc. (-1.34),
Company | PE Ratio | Market cap |
---|---|---|
-6.50 | $607.51M | |
-5.12 | $2.76B | |
-7.39 | $1.25B | |
-6.06 | $549.60M | |
-428.77 | $31.68B | |
-9.04 | $639.91M | |
-26.44 | $5.47B | |
-15.28 | $5.00B | |
-2.10 | $107.81M | |
4.06 | $71.07M | |
-0.45 | $29.58M | |
-0.78 | $92.68M | |
-0.98 | $8.20M | |
9.19 | $93.74M | |
-0.65 | $39.73M | |
-1.34 | $692.60M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ProQR Therapeutics N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ProQR Therapeutics N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ProQR Therapeutics N.V.'s PE Ratio?
How is the PE Ratio calculated for ProQR Therapeutics N.V. (PRQR)?
What is the highest PE Ratio for ProQR Therapeutics N.V. (PRQR)?
What is the 3-year average PE Ratio for ProQR Therapeutics N.V. (PRQR)?
What is the 5-year average PE Ratio for ProQR Therapeutics N.V. (PRQR)?
How does the current PE Ratio for ProQR Therapeutics N.V. (PRQR) compare to its historical average?